8 completed, 7 unknown, 3 recruiting, 3 terminated. 14 Phase 2, 13 Phase 1, 1 Not applicable, 1 Phase 3.
Follow T Cell Lymphoma: new trials by email Literature Review of T Cell Lymphoma trials Research Report on T Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies HY035 cell injection - Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory | Phase 1 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 13 | 2026-08-15 | 2026-08-25 |
| A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma. PTCL, T Cell Lymphoma | Not yet recruiting | Ruijin Hospital | 1000 | 2026-06-01 | 2026-06-18 | |
| CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation CD7 CAR-T combined with autologous hematopoietic stem cell transplantation - CD7+ Lymphoma, T Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Zhengzhou University | 38 | 2025-09-01 | 2025-08-12 |
| Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol - T Cell Lymphoma, T-cell Lymphoma | Phase 2 | Recruiting | Yale University | 22 | 2024-10-09 | 2026-04-14 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies CTX131 - T Cell Lymphoma, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics | 12 | 2024-08-13 | 2026-04-03 |
| Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-07-10 | 2024-11-12 |
| Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen - T Cell Lymphoma | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 23 | 2023-04-01 | 2023-03-16 |
| A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma Selinexor - Lymphoma, DLBCL | Unknown | Ruijin Hospital | 250 | 2022-12-15 | 2023-05-10 | |
| Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) ACHOP - T Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Won Seog Kim | 41 | 2022-07-01 | 2023-10-23 |
| Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma Chidamide combined with BEAM - T Cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 23 | 2022-05-28 | 2022-09-29 |
| Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Completed | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 102 | 2022-02-21 | 2025-01-20 | |
| Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma chimeric antigen receptor T cell treatment - T Cell Lymphoma, T-cell Leukemia | Phase 1 | Completed | Beijing Boren Hospital | 16 | 2021-09-14 | 2024-11-14 |
| LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Efficacy of LCAR-T2C CAR-T cells - T Cell Lymphoma, T-cell Leukemia | Phase 1 | Terminated | Beijing Boren Hospital | 9 | 2021-07-02 | 2022-08-16 |
| CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. HSP-CAR30 - Hodgkin Lymphoma, Adult, T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 30 | 2020-09-29 | 2020-12-04 |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) CTX130 - T Cell Lymphoma | Phase 1 | Terminated | CRISPR Therapeutics AG | 49 | 2020-07-31 | 2025-01-08 |
| Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas Brentuximab Vedotin - T Cell Lymphoma | Phase 2 | Withdrawn | University of Kansas Medical Center | 2020-05-29 | 2023-02-03 | |
| Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Tenalisib, Romidepsin - T Cell Lymphoma | Phase 1 / Phase 2 | Completed | Rhizen Pharmaceuticals SA | 33 | 2019-03-12 | 2022-10-28 |
| Allo-HSCT as First-line Consolidation in High-risk PTCL T Cell Lymphoma | Unknown | Peking University People's Hospital | 50 | 2019-01-01 | 2022-08-02 | |
| Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells AUTO CAR T cell therapy - Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma | Phase 2 | Enrolling by invitation | Autolus Limited | 500 | 2018-08-02 | 2026-09-22 |
| Trial of Endostar Combined With CHOPT for T Cell Lymphoma Endostar and CHOPT - T Cell Lymphoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2011-06-01 | 2015-11-04 |
Showing 20 of 26. Sign in to see all of them.
Lymphoma, T-Cell (26) · Lymphoma (4) · Leukemia (3) · Leukemia, T-Cell (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, T-Cell, Peripheral (2) · Recurrence (2) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Hairy Cell (1) · Leukemia, Prolymphocytic, T-Cell (1)
Hemic and Lymphatic Diseases (26) · Immune System Diseases (26) · Immunoproliferative Disorders (26) · Lymphatic Diseases (26) · Lymphoproliferative Disorders (26) · Neoplasms by Histologic Type (26) · Lymphoma, Non-Hodgkin (25) · Neoplasms (25) · Lymphoma (22) · Hematologic Diseases (9) · Leukemia, Lymphoid (7) · Leukemia (5) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4)
endostar protein (2) · Azacitidine (1) · Brentuximab Vedotin (1) · CHOEP protocol (1) · Clinical Protocols (1) · Cyclophosphamide (1) · Doxorubicin (1) · EPOCH protocol (1) · Endostatins (1) · Etoposide (1) · N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (1) · Prednisone (1) · Sorafenib (1) · Vincristine (1) · fostamatinib (1)
Ruijin Hospital (3) · Beijing Boren Hospital (2) · Yale University (2) · Amgen (1) · Autolus Limited (1) · CRISPR Therapeutics (1) · CRISPR Therapeutics AG (1) · Emergent BioSolutions (1) · Essen Biotech (1) · Fudan University (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Nevada Cancer Institute (1) · Peking University People's Hospital (1)
China (10) · United States (10) · Australia (2) · Canada (2) · Spain (2) · Italy (1) · South Korea (1) · United Kingdom (1)
Abhay Patki, PhD (1) · Alissa Keegan, MD, PhD (1) · Alissa Keegan, PhD (1) · Delva Deauna-Limayo, MD (1) · Francine Foss, MD (1) · Jeffrey Skolnik, MD (1) · Junning Cao, MD (1) · Kai Hu, MD/PhD (1) · Lucia Catani, PhD (1) · Sid Ganguly, MD (1) · Tarsheen Sethi, MD (1) · Xiao-Jun Huang, MD (1)